how bad is semaglutide for you What Should I Expect the First Week of GLP-1 What Should I Expect During

Other Options May Be More Appropriate For Individuals Who: Require clinically demonstrated weight loss

Wegovy contains Semaglutide 0.25 mg , a once-weekly injectable used for: Key uses of Wegovy 0.25 mg include: Semaglutide is a GLP-1 receptor agonist

Or perhaps youre looking to achieve your ideal weight as part of your New Years resolution

To view a copy of this licence, visit About this article Cite this article Anastasiou, I.., Argyrakopoulou, G., Dalamaga, M

Carry forward the habits that moved the needle

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators